Prof Peter Czabotar
Honorary (Professorial Fellow)
Department of Medical Biology (WEHI)
122 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
Towards a molecular and structural definition of cell death
DOI: 10.1038/s41594-025-01646-x2025
Journal article
Computational design of potent and selective binders of BAK and BAX
DOI: 10.1126/sciadv.adt41702025
Journal article
The BCL-2 protein family: from discovery to drug development
DOI: 10.1038/s41418-025-01481-z2020
Journal article
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
DOI: 10.1182/BLOOD.20190042052019
Journal article
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
DOI: 10.1038/s41467-019-10363-12019
Journal article
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
DOI: 10.1111/bjh.160692019
Journal article
Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
DOI: 10.1158/2159-8290.CD-18-1119
RECENT SCHOLARLY WORKS
2025
Journal article
Structure–activity analysis of imino-pyrimidinone-fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors
DOI: 10.1111/febs.700382025
Journal article
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules
DOI: 10.1126/sciadv.adr81462025
Journal article
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
DOI: 10.1182/bloodadvances.20240144462025
Journal article
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
DOI: 10.1038/s41467-025-57905-42024
Conference Proceedings
Structure, function, surf, repeat: A week at Lorne Proteins 2024
DOI: 10.1016/j.str.2024.10.0072024
Journal article
Death at a funeral: Activation of the dead enzyme, MLKL, to kill cells by necroptosis
DOI: 10.1016/j.sbi.2024.1028912024
Journal article
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cells
DOI: 10.1038/s41418-024-01289-3